Angiotensin‐converting enzyme inhibitor (ACE‐I) and angiotensin‐receptor blocker (ARB) users may be associated with increased mortality in patients with post‐operative acute kidney injury (AKI), but data are limited. We studied whether… Click to show full abstract
Angiotensin‐converting enzyme inhibitor (ACE‐I) and angiotensin‐receptor blocker (ARB) users may be associated with increased mortality in patients with post‐operative acute kidney injury (AKI), but data are limited. We studied whether users of ACE‐I/ARBs with AKI after colorectal cancer surgery (CRC) were associated with increased 1‐year mortality after AKI.
               
Click one of the above tabs to view related content.